Ulcerative Colitis

Probiotic VSL#3 shows promise for ulcerative colitis patients with pouchitis

Published in Gastroenterology Week, January 26th, 2004

Further evidence that manipulating the intestinal flora with a highly concentrated probiotic may be an effective therapeutic strategy for patients with inflammatory bowel disease (IBD) was reported in this month's issue of the medical journal Gut.

In the year-long, placebo-controlled study, once daily treatment with the probiotic preparation VSL#3 was shown to be highly effective in maintaining antibiotic-induced remission of a post-surgical complication called pouchitis in patients with ulcerative colitis (UC) who have had their colons surgically removed.

Additionally, patients in the study who took VSL#3 reported improved quality of life...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gastroenterology Week

Source: Gastroenterology Week (2004-01-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry